Swedish Medical Products Agency approves Hansa Medical’s clinical Phase II-study application with IdeS
Hansa Medical announces the Swedish Medical Products Agency’s approval of the application to carry out a clinical Phase II-study with the drug candidate IdeS. The study’s primary objective is to investigate IdeS’ efficacy and safety in sensitised kidney transplantation patients. The Phase II-study will be conducted at Uppsala University Hospital and is scheduled to begin in the second quarter of 2014.The drug candidate IdeS is developed for fast and efficient inactivation of circulating IgG-antibodies in sensitised patients awaiting kidney transplants. The ambition is to enable